Here are the 10-K annual reports from Wave Life Sciences Ltd. (WVE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow WVE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WVE filings page.
Wave Life Sciences Ltd. filed an amendment to its annual report to provide detailed Part III information on directors, executive officers, governance and executive compensation for the year ended December 31, 2025. The company highlights a nine‑member board, fully independent key committees, and strong say‑on‑pay support.
The amendment describes 2025 business milestones across obesity, genetic liver and neuromuscular programs, a major collaboration with GSK, and a December 2025 equity financing that raised approximately $402.5 million, ending the year with $602.1 million in cash and cash equivalents. It also explains performance‑based cash bonuses, multi‑year option and RSU grants, and severance and change‑of‑control protections for senior leaders.
Wave Life Sciences Ltd. provides an annual overview of its business, pipeline and risks as a clinical-stage RNA medicines company. The company focuses on obesity, alpha-1 antitrypsin deficiency (AATD), PNPLA3 I148M liver disease, Duchenne muscular dystrophy and Huntington’s disease using its PRISM chemistry platform.
Lead programs include WVE-007 for obesity, WVE-006 for AATD and WVE-008 for PNPLA3 I148M liver disease, alongside WVE-N531 for DMD and WVE-003 for allele-selective Huntington’s disease. As of June 30, 2025, the aggregate market value of non-affiliate shares was $851,013,538, and ordinary shares outstanding were 188,254,954 as of February 19, 2026.